Related Experiment Videos

Clozapine-induced neutropenia in children: management with lithium carbonate

Alexandra Sporn1, Nitin Gogtay, Roberto Ortiz-Aguayo

  • 1Child Psychiatry Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA.

Journal of Child and Adolescent Psychopharmacology
|December 4, 2003
PubMed

Insights

Lithium carbonate can safely manage clozapine-induced neutropenia in children with early-onset schizophrenia. This strategy allows for continued clozapine treatment, improving white blood cell counts.

Area of Science:

  • Pediatric Psychiatry
  • Pharmacology
  • Hematology

Background:

  • Clozapine is highly effective for treatment-resistant schizophrenia but carries a risk of neutropenia and agranulocytosis.
  • Neutropenia risk is elevated in pediatric patients treated with clozapine.
  • Very early onset schizophrenia presents unique treatment challenges in children.

Observation:

  • Two pediatric patients (7 and 12 years old) with very early onset schizophrenia developed neutropenia during clozapine therapy.
  • Lithium carbonate was added to the treatment regimen in both cases.
  • White blood cell (WBC) and neutrophil counts increased after lithium addition.

Findings:

  • Adjunct lithium carbonate successfully elevated WBC counts, enabling clozapine rechallenge in pediatric patients.
  • Long-term coadministration of clozapine and lithium maintained stable WBC and neutrophil counts.
  • Therapeutic lithium blood levels (0.8-1.1 microg/mL) were associated with sustained hematological stability.

Implications:

  • Lithium carbonate represents a safe and effective adjunct therapy for managing clozapine-induced neutropenia in children.
  • This approach may expand the use of clozapine in pediatric populations requiring treatment for schizophrenia.
  • Further research into lithium's role in mitigating clozapine-related hematological side effects is warranted.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...